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Parkinson disease is a progressive neurodegenerative disorder. In Europe 108 out of 
100.000 people suffer from Parkinson disease. The key motor symptoms are tremor, 
rigidity, bradykinesia and postural instability, also non-motor symptoms such as cogni-
tive impairments and mood changes appear. Parkinson disease is neuropathologically 
recognized by loss of dopamine cells in a specific part of the brain and the presence of 
Lewy bodies (a misfolded proteïn). In the early stages of the disease motor symptoms 
can be adequately improved by oral dopamine drug replacement therapy. Unfortunate-
ly, the beneficial effects wear off progressively and ‘on-off’ fluctuations and L-dopa 
induced dyskinesias appear. In this stage of disease deep brain stimulation is the first 
choice therapy. Since the introduction of deep brain stimulation of the subthalamic 
nucleus in 1993, this therapy has proven to be effective on the short and long term. 
However, in a substantial number of patients neuropsychiatric side effects are seen. In 
this thesis we investigated the pathophysiological mechanisms of these side-effects and 
tried to overcome these by pre-clinical experiments in an animal model of Parkinson 
disease and by an electrophysiological approach in Parkinson patients during deep brain 
stimulation surgery.  
 
In the first chapter of this thesis we show the short and long term outcome of subtha-
lamic nucleus deep brain stimulation in our cohort of patients. We learned that some 
neuropsychiatric symptoms are present in some patients. We have seen an increased 
impulsivity in younger patients, whereas general cognitive problems were seen in older 
patients. As reported in literature we also have seen deterioration in gait after 10 years. 
This chapter shows that the issues raised in the international literature are also present 
in the Dutch population and therefore in need for further studies to overcome these 
problems. 
 
In chapter 2 we investigated the behavioral side-effects in a rodent. We used a widely 
used model for Parkinson disease, namely the 6-OHDA model. We found behavioral 
deficits which are related to the serotonin system, which is involved in depression. Next 
we tested the connection between the subthalamic nucleus and the dorsal raphe nu-
cleus, a brainstem region in which serotonin is produced. We found changes using im-
muno-histochemical markers, which underline the fact that deep brain stimulation of 
the subthalamic nucleus affects the serotonin system. This finding led to further scien-
tific investigations in animal models as well as in Parkinson patients and might be a first 
step in overcoming depressive symptoms induced by subthalamic nucleus stimulation.  
 
In chapter 3 a review of the literature was performed to investigate the cortical connec-
tions with the subthalamic nucleus. The findings of this literature review were necessary 
for the experiments in chapter 4 and 5. 
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In chapter 4 we tested deep brain stimulation in certain brain areas in animals to treat 
depression. The mechanism behind the efficacy of stimulation of these areas is still not 
fully understood. Since the STN is also connected to these areas we investigated which 
part and to what extend the STN is involved. The findings of this experiment help the 
scientific community to understand the mechanisms behind the efficacy of deep brain 
stimulation in depression and might in the end lead to novel therapeutic options for 
depressive patients.  
 
In chapter 5 we tested if the subthalamic nucleus has three independent subdomains 
with different functionality. We tested this using an electrophysiological approach in an 
animal model. We learned that there is a partition seen, but overlap is present. This 
finding has clinical implications for deep brain stimulation of the subthalamic nucleus in 
Parkinson patients. Pure selective stimulation to reduce motor symptoms without in-
ducing undesired behavioral side effects might thus not be possible. This has direct 
consequences for these patients. 
 
In chapter 6 and 7 we aimed to overcome undesired side-effects of deep brain stimula-
tion of the subthalamic nucleus in Parkinson patients by applying stimulation of the 
superficial brain region which corresponds with motor function. This technique was 
promising and if the responses acquired would have been clearer, it would have been 
possible to further improve the motor symptoms without inducing the undesired be-
havioral side-effects. This would have reduced medical costs significantly. 
 
In chapter 8 we assessed a novel tool to assess gait in an animal model of Parkinson 
disease. Gait as shown in chapter 1 is a major problem in patients with advanced stages 
of Parkinson disease. Thus far no therapies are available to treat this symptom. Falls 
lead to hospital admissions and hip-fractures. This study was necessary to be able to 
further investigate gait problems in animal models to be able to develop novel therapies 
for the gait disturbances. If a treatment can be developed this leads to lesser burden for 
the patients and caregivers, as well as a reduction in medical costs. 
 
In chapter 9 we performed a basic scientific experiment which helps us to understand 
the pathophysiology in Parkinson disease. The results of this experiment contributed to 
the basic knowledge of the scientific community. 
 
In summary, the experiments performed in this thesis consisted of clinical experiments 
with patients, experiments with animal models and a review of the literature. The scien-
tific approaches used were well reasoned. The approaches chosen depended on the 
research question which needed to be answered. Although we are aware that the trans-
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lation of animal data to humans is often difficult, animal research is indispensable to 
establish advances in neuroscience. In my opinion, not only clinical studies, but also pre-
clinical experiments using animal models are thus necessary to sustain the high quality 
of our medical care and basic scientific knowledge. I therefore encourage the European 
and Dutch Government, as well as private funding programs to keep funding basic sci-
entific research in which animal research is involved.  
  
